The Drug Development Pipeline for Infusible Therapies—Clinical and Business Implications!
May 14, 2008
12:00-1:30pm ET
1.5 contact hours*
ACPE #: 207-999-08-042-L04-P
As the drug development pipeline shifts towards biotech therapies, alternate-site infusion organizations will be involved in providing approximately 20% of these therapies. This modification could translate into higher revenues for your infusion business—but are you equipped to plan for such therapies? Find out by participating in this unique audio conference and obtain valuable information to enhance your strategic direction, based upon these pipeline opportunities!
Program Description:
This educational program provides an overview of infusible therapies that will require a service component. The pipeline therapies will be organized by indication and date of expected launch, offering a valuable review for clinicians and senior managers involved in planning future product and service lines.
Educational Objectives:
After completion of the program the participant will:
- Outline the infusible therapies in the drug development pipeline.
- Discuss the indication for each drug therapy in development.
- Describe strategies to provide care management for these therapies at your alternate-site organization.
Come and learn with your fellow colleagues about this subject and how it will impact the bottom-line at your organization. Reserve your spots early. Remember, these audios make great training sessions—as one phone line can train unlimited number of people (see below for additional requirements for those seeking pharmacy continuing education!*
Faculty:
Stacey Ness, PharmD, Manager, Clinical Services, BioScrip, Eden Prairie, MN
Faculty Bio:
Stacey Ness is a clinical services manager for BioScrip specialty pharmacy supporting BioScrip's infusion services, specialty pharmacy operations, and pharmacy benefit divisions. Areas of interest include designing adherence and persistency programs in partnership with pharmaceutical companies and payers—with a concentration on adherence and persistency of biologic therapies and oral oncolytics. She is also interested in working with patient advocacy and support groups. Previous professional experiences include anti-coagulation and transplant patient management.
Ms. Ness graduated with a Doctor of Pharmacy degree from the University of Minnesota and currently serves on the Minnesota Medicaid Drug Formulary Committee.
Pharmacy Continuing Education:
To apply for continuing education credit in pharmacy for this program, please do the following:
- Kindly complete the evaluation form and the Statement of Continuing Education Credit form for this audio conference. You will receive the link to these forms in an email 24-48 hours prior to the audio conference.
- Fax the evaluation and certificate forms to the attention of Eleanor Nespica at 703-683-1484.
- Your certificate for continuing education will be validated and faxed to you within three – four weeks of NHIA’s receipt of all completed forms.
- Please be aware that you are responsible for filing a copy of your certificate with your state board(s).
*Note: To receive Pharmacy Continuing Education credit, registered participants must individually sign-in to the call and attend the entire audio conference. Only paid registrants for this audio conference are eligible for Continuing Education credit. Parties who listen to the audio conference, but who have not paid, registered and called-in individually, cannot be granted Continuing Education. If you have any questions regarding Continuing Education Credit for this program, please contact Eleanor Nespica, Education Programs Manager, at the NHIA office: 703-549-3740 or eleanor.nespica@nhia.org
Target Audience:
Clinicians and senior managers in the alternate-site infusion field.